Hints and tips:
Related Special Reports
Related Topics
...Powell said investors worried that Pfizer had paid a lot for what it had bought....
...Because the European market is saturated with the BioNTech/Pfizer and Moderna shots, it remains unclear what impact on its revenues an approval might have....
...Pfizer declined to comment, citing confidentiality, as did the Commission....
...Pfizer said the discussions had been conducted “in good faith” and remained “confidential”....
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
Case studies in best practice among general counsel and company legal teams in North America
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...Yet Pfizer’s $19bn in Paxlovid sales were almost a fifth of its 2022 total....
...BioNTech has written down about €900mn on its Covid-19 vaccines because of lower than expected demand for the shots it developed with partner Pfizer....
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...“Nobody at Pfizer ever told Mr Dagar, who was on the ‘blinded’ side, the results of the Paxlovid trial,” he added....
...Pfizer on Tuesday raised $31bn in a jumbo-sized bond sale that will help fund the takeover....
...Meanwhile Pfizer’s own shares, down more than a fifth this year, have underperformed peers....
...Haleon declined to comment on Pfizer’s plans....
...US pharmaceutical company Pfizer sold the shots, developed with Germany’s BioNTech, for about $19 a dose under the contract signed in 2021, but the new price has not been disclosed....
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Shares in Pfizer added about 1 per cent on Friday, while Seagen was up about 0.9 per cent....
...Pfizer believes that in 2030 Seagen could contribute more than $10bn in risk-adjusted revenues....
...The drugmakers Pfizer and Roche said they are piloting use of rFC at some of their facilities....
...The downbeat forecasts contrast with a stellar performance by Pfizer in 2022. Pfizer reported earnings per share of $6.58 in 2022, a record for the 174-year-old company....
International Edition